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Abstract
Background: Approximately one-third of acquired immunodeficiency syndrome cases in the
United States are associated with the practice of sharing of injection equipment and are preventable
through the once-only use of syringes, needles and other injection equipment.
Discussion: Sterile syringes may be obtained legally by 4 methods depending on the state. They
may be purchased over the counter, prescribed, obtained at syringe exchange programs or
furnished by authorized agencies. Each of these avenues has advantages and disadvantages;
therefore, legal access through all means is the most likely way to promote the use of sterile
syringes.
Summary: By assisting illicit drug injectors to obtain sterile syringes the primary care provider is
able to reduce the incidence of blood borne infections, and educate patients about safe syringe
disposal. The provider is also able to initiate discussion about drug use in a nonjudgmental manner
and to offer care to patients who are not yet ready to consider drug treatment.
Background
Approximately one-third of acquired immunodeficiency
syndrome cases in the United States are associated with
the practice of sharing of injection equipment [1]. Injec-
tion drug use is also the principal mode of hepatitis C
transmission. The majority of these infections can be pre-
vented through the once-only use of syringes, needles and
other injection equipment as recommended by the U.S.
Department of Health and Human Services [2].
There is strong evidence that injection drug users (IDUs)
are capable of altering their injecting behaviors, thus pre-
venting the spread of disease. Injection drug users began
to hear educational messages about transmission of infec-
tious diseases through injection and means of prevention
in the late 1980's. In New York City bleach kits were dis-
tributed and in 1992 several syringe exchange programs
(SEPs) began legal operation. Between 1990 and 1997
IDUs in New York City reported significant declines in
risky injection practices [3] and the prevalence of HIV
among IDUs dropped from 50% to 30% by 2000 [4].
These data indicate that given necessary education and
tools, drug users can make significant changes in behav-
ior. In light of numerous reports documenting the efficacy
of syringe exchange [5-7] many professional associations
have called for the elimination of barriers that limit access
to sterile syringes as an important way to further reduce
transmission of infections through injection drug use.
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Sterile syringes may be obtained legally by 3 methods
although their availability varies considerably from state
to state. They can be purchased over the counter, pre-
scribed, or obtained at SEPs or other authorized agencies.
Many states do not require prescriptions for syringes and
since the beginning of the HIV epidemic, twelve states
(Connecticut, Hawaii, Illinois, Maine, Minnesota, New
Hampshire, New Mexico, New York, Oregon, Rhode
Island, Washington, and Wisconsin8) have changed their
syringe access laws making it possible to obtain syringes
over the counter. In many states, syringes can be legally
prescribed by health care professionals for drug injection
by IDUs (Table 1) [8,9]. As of 1998, at least 131 SEPs were
operating in 31 states (Table 2) [10]. Not all of these have
a clear legal basis. Twelve states and the District of Colum-
bia have affirmatively authorized SEPs. Ten jurisdictions
have passed statutes establishing programs (Connecticut,
District of Columbia, Hawaii, Maine, Maryland, New
Mexico, Rhode Island and Vermont) or authorizing local
governments to do so (California and Massachusetts). In
New York, syringe exchange programs are authorized by
the Commissioner of Health, exercising power granted in
the paraphernalia law to waive its application. In the state
of Washington, local health officials secured a declaratory
judgement from the state Supreme Court holding that the
paraphernalia law did not prohibit them from authoriz-
ing SEPs, a ruling that was later codified by the legislature.
Each of these options has its own strengths and limita-
tions; different groups of IDUs are more likely to use phar-
macies while others are more likely to use syringe
exchange programs [11]. The availability of all options is
the most effective way to provide maximum access for
injection drug users. This article describes and discusses
the various options for legal syringe access for injection
drug users.
Discussion
Syringe Prescription
The American Medical Association endorsed prescription
of syringes by physicians through a policy adopted at its
Annual Meeting held in June 2000:
" ... the American Medical Association strongly supports
the ability of physicians to prescribe syringes and needles
to patients with injection drug addiction in conjunction
with addiction counseling in order to help prevent the
transmission of contagious diseases." [12]
Until recently it was widely assumed that the laws in many
states prohibited the prescription of syringes for the pur-
pose of injecting illicit drugs. In August 2000 the Project
on Harm Reduction in the Health Care System from Tem-
ple University Law School released a comprehensive study
of syringe prescription laws in all 50 states concluding
that prescription of syringes for the prevention of disease
is legal in many states. The barriers to prescription in each
state are also discussed. These documents, updated to
include legal changes through June 2003, may be found
at: http://www.temple.edu/lawschool/aidspolicy/
default.htm[13].
The prescription of syringes can potentially prevent
bloodborne disease by providing a sufficient supply of
clean syringes to injectors. Furthermore it offers an
opportunity to attract and retain a population at risk of
many health problems which may otherwise be difficult
to engage in care. By offering syringes, the prescriber
makes it clear that he or she is concerned about the
patient's well-being even if drug use continues. This con-
cern can promote honest dialogue about drug use, per-
haps encouraging a patient to acknowledge for the first
time to the physician that they are using drugs. In other
cases, it opens the door to acceptance of drug treatment
[14] or other interventions to reduce the harm of contin-
ued drug use, such as the provision of take-home
naloxone for use in the event of overdose [15].
The chief drawbacks to the prescription of syringes in
states where the practice is legal are the lack of explicit
authorization for the practice and the related perception
that law enforcement officials opposed to the practice
would find some legal basis to prosecute physicians who
prescribe syringes [13]. Another drawback to prescription
of syringes is that drug users report a lack of access to pri-
mary health care, often because they have no health insur-
ance [16,17]. They may also be deterred by the perception
that many physicians would prefer not to care for them
because of their drug use [18].
Table 1: States in which Physician Prescription of Sterile Injection 
Equipment and Pharmacy Sale of Prescribed Syringes are Clearly 
Legal to Prevent Disease Transmission
AK CA CO CT HI
IL IN LA MA ME
MI MN MT NV NH
NJ NM NY OR PA
PR RI SC TN VA
WA WV WI
Table 2: States with Syringe Exchange Programs * Receive public 
funding ** Shut down
CA* (21); NY*(14); WA* (12); NM* (9); CT* (6); MA *(5)
MI, OR*, PA*, WI* (3 each);
CO*, Il*, IN, MN, MT, OH, PR*, TX, (two each)
AK, AZ*, DC, GA, HA*, KS, LA, MD*, NC, NH, NJ **, OK, RI*, TN, 
and UT (1 each).
*Receive public funding ** Shut downBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/37
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Non-prescription Pharmacy Sales
Pharmacies provide another option for syringe access
through over-the-counter sales. They are easy to access in
most communities, and have long hours of operation.
Pharmacists are trained health care professionals who can
offer health education to their customers. Syringes are
available anonymously on a walk-in basis. Pharmacy sales
of syringes in Connecticut and Minnesota were evaluated
and found to be effective in reducing risky injection
behaviors [19,20] and were not shown to increase drug
use [19]. Pharmacy sales also provide an impetus to pro-
mote safe disposal [21,22]. However, not all pharmacies
in states allowing sales choose to sell syringes without a
prescription, perhaps because they do not want drug users
as clientele or are concerned that they may promote drug
use [23].
Free distribution by Syringe Exchange Programs
Syringe exchange programs are staffed by persons who
have significant expertise in addressing the needs facing
injection drug users. In addition to syringes, IDUs may
also receive a variety of services such as education about
safer injection, proper syringe disposal, referrals to drug
treatment, referrals to medical care, and public health
services such as HIV counseling and testing and tubercu-
losis screening [10]. Like pharmacies, they require no
appointment or identification. Because they rely on
exchange of used syringes for sterile ones syringe disposal
is also an integral part of the service. Syringe exchange
programs have been extensively evaluated and have been
found to be effective in preventing disease without pro-
moting drug use [5-7,24]; they have also been found to be
cost effective [25]. The chief drawback to SEPs is their lack
of accessibility; there are approximately 130 exchanges in
the entire United States. SEPs also require that partici-
pants carry and return medical waste containing drug res-
idue that may put them at risk of arrest [26]. Also, SEPs are
not routinely staffed by licensed health professionals
available during all hours of operation.
Free or Fee-Based Provision by Clinicians
In New York State, under a current demonstration pro-
gram, hospitals, clinics and those practitioners authorized
to prescribe syringes are able to furnish (provide access
either through sales or at no cost) up to 10 syringes per
encounter. Like prescribing syringes, this option opens a
dialogue with a clinician about drug use. When health
care providers offer this service, the step of visiting the
pharmacy is eliminated, which may be important when
the patient has little money or wishes to maintain confi-
dentiality about his or her drug use. The program is cur-
rently under evaluation, however potential drawbacks
include the fact that currently no specific funding is allo-
cated for the furnishing of syringes and as of December
2002 only 41 non-pharmacy providers had registered to
provide syringes. Furthermore 10 syringes, if used only
once per injection, will not last a regular drug user long;
the average number of injections per day is estimated to
be 2.8 [27].
Treating Injection Drug Users
In addition to preventing bloodborne infections, provid-
ing illicit drug injectors access to sterile syringes both
directly and by referral presents an important opportunity
to improve communication between medical providers
and their drug using patients [14]. Physicians have been
noted to be uncomfortable treating patients with sub-
stance abuse disorders. Some of this may be attributed to
a lack of training in the causes and treatments of substance
abuse [18]. Furthermore, medical providers are generally
trained to encourage abstinence only, whether or not the
patient desires it or is able to achieve it. As a basic medical
text states, "The goals of treatment for persons who are
dependent on psychoactive substances can be divided
into three major components: the achievement of absti-
nence, relapse prevention, and rehabilitation." [28]. How-
ever, physicians are most likely to encounter drug-using
patients who are unable or unwilling to achieve absti-
nence, unable to access treatment or who continue to use
drugs despite treatment. The discrepancy between what is
taught formally in medical schools and what is encoun-
tered in practice may further contribute to the dissatisfac-
tion physicians experience in caring for drug users. There
are a variety of ways that a primary care provider can pro-
vide care for active drug users (Table 3). Medical schools
should plan curricula to close this gap while practicing
physicians should be encouraged to seek out Continuing
Medical Education programs to become further educated
about the problems of injection drug users.
Even patients who wish to stop using drugs face obstacles
to achieving that goal. There are insufficient treatment
slots in most parts of the country. For example, while
methadone maintenance has been shown to be a highly
effective treatment for heroin, the number of available
slots is sufficient to serve at most 30% of heroin addicts
Table 3: Steps for physicians caring for active injection drug users
• Discuss injection drug use in a nonjudgmental manner at all routine 
visits
• Participate in CME related to the problems of injection drug users
• Become educated about commonly used substances
• Facilitate access to clean syringes for injectors through prescription 
or referral
• Educate patients about safer injection practices
• Inform patients about proper disposal of syringes
• Be aware of drug treatment options in the community
• Consider prescription of buprenorphine to heroin addictsBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/37
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[29]. The recent approval of office based treatment of opi-
oid addiction with buprenorphine may alleviate this
shortage; physicians treating even a small number of opi-
oid addicts may benefit their patients by becoming quali-
fied to provide this medication [30,31].
Cocaine treatment slots are also scarce and furthermore,
while many compulsive users cease or moderate use, more
effective therapeutic modalities for cocaine addiction are
desperately needed [32]. When the physician can offer
additional meaningful interventions, such as providing
syringes to prevent infection and education about how to
reduce other risks, he or she may feel increased satisfac-
tion in caring for drug using patients. Education is key;
these patients may not otherwise have an opportunity to
discuss drug use and injection with anyone knowledgea-
ble about its health risks. Education may be needed about
safe injection, about the substances used, and about
options for treatment. When patients can be honest about
their drug use they can ask questions about possible drug
interactions and be more open about how drug use may
impact their health.
Drug users also have medical needs, both for routine care
and for care related to drug use such as HIV, the need for
hepatitis B vaccine, or treatment for hepatitis C [33].
Improved rapport with medical providers may facilitate
treatment and prevention activities. Finally, increased
healthcare utilization, including ambulatory medical care,
is also associated with entry into drug treatment.
Increased willingness to treat drug users that leads to
attendance at medical appointments by drug users may
therefore also lead to reductions in drug use for some
patients [34].
Major public health and economic benefits also accrue
from the prevention of bloodborne infections among
IDUs. For example, HIV may be transmitted to sex part-
ners and to children of an infected drug user. HIV infec-
tion is expensive; the lifetime cost of one infection is
estimated to be at least $195,000 [35], equal to the cost of
well over 2 million syringes. Increasing access to sterile
injection equipment is included in recent Centers for Dis-
ease Control recommendations on how primary care pro-
viders can incorporate prevention of HIV transmission
when providing care to persons living with HIV [36].
Additionally, when the use of syringes is discussed with
patients, proper disposal of used syringes may also be
addressed. Proper syringe disposal is poorly managed
among both diabetics and injection drug users [26,37];
education of both groups may be beneficial. Legal access
to syringes may also contribute to proper disposal as drug
users report being more likely to dispose of syringes safely
when obtained legally [38]. In New York State pharmacy
sales of syringes have not resulted in an increase in
syringes on the street or improperly disposed of in the
trash [39,40]. Patient education materials such as those
provided by the American Medical Association can also
facilitate education about disposal [41].
Some may question whether providing access to syringes
for the harmful act of injecting illicit drugs is ethical. For
example, it may be argued that the potential for harm
from injection violates the principle of nonmaleficence.
However the prevalence of bloodborne infections attests
to the fact that lack of a sterile syringe is not a deterrent to
injection drug use and that the likelihood of harm to the
patient and his or her contacts is high in the absence of
sterile syringe access. In fact some might argue that failure
to provide access could be considered "failure to guard
against risks of harm to others"[42], and a violation of the
principle of nonmaleficence. Ensuring access to sterile
syringes clearly upholds the principle of beneficence as it
has the potential to prevent irreversible harm, not only to
the recipient but to the general public by reducing trans-
mission to sexual partners and children of injection drug
users. In addressing ethical issues, the Project on Harm
Reduction concludes that not only is provision of sterile
syringes to drug users ethical, but also that "physicians
treating patients who inject drugs are, at least in the
absence of legal limits, obliged by their own professional
standards to consider providing this care to patients who
need it." [13]
Communities wishing to achieve maximal availability of
sterile syringes may opt to offer all avenues of access to
sterile syringes. Injection drug users would be more likely
to use a sterile syringe each time they inject if multiple
sources were available for procuring them. All primary
care providers should be aware of the resources that are
available for the provision of syringes and their proper
disposal in their communities. Those treating significant
numbers of injection drug users may wish to become
active in promoting additional resources, and advocate
for syringe availability in areas with limited access. By
increasing access to sterile syringes through all potential
methods bloodborne diseases may be effectively pre-
vented, which will benefit not only injection drug users
but also the wider public. Both economic benefits and
enhanced public health will be realized.
Summary
Legal access to sterile syringes for injection drug users can
decrease syringe sharing and disease transmission. Sterile
syringes may be obtained legally by 3 methods depending
on the state. Each of these avenues has advantages and dis-
advantages; therefore, legal access through all means is the
most likely way to promote the use of sterile syringes. By
assisting illicit drug injectors to obtain sterile syringes the
primary care provider is able to reduce the incidence ofBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/37
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blood borne infections, and educate patients about safe
syringe disposal. The provider is also able to initiate dis-
cussion about drug use in nonjudgmental manner and to
offer care to patients who are not yet ready to consider
drug treatment.
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